Table A3.
A non-exhaustive list of patents related to Erbitux® (cetuximab) as of May 2019.
| Subject | Patent number | Date of filing | Applicant | Status |
|---|---|---|---|---|
| Anti-EGFR mAb | EP0359282 (parent) | 15.09.1989 | Rorer International | Expired on 15.09.2009 |
| EP0667165 | Expired on 15.09.2009 | |||
| Liquid formulation | EP1406658 | 18.06.2002 | Merck | Deemed to be withdrawn |
| Lyophilized formulation | EP1455824 | 25.11.2002 | Merck | Active until 25.11.2022 |
| Aqueous composition | EP1687031 | 26.10.2004 | Merck | Revoked |
| Crystal form | EP1686961 (parent) | 12.11.2004 | Merck | Refused |
| EP1974723 | Deemed to be withdrawn | |||
| Process for highly concentrated formulation | EP1713502 | 27.01.2005 | Merck | Deemed to be withdrawn |
| Prediction method | EP1869208 | 12.04.2006 | Merck | Refused |
| Prediction method | EP1934599 (parent) | 11.10.2006 | Merck | Deemed to be withdrawn |
| EP2251688 | Deemed to be withdrawn | |||
| Prediction method | EP2443252 | 15.06.2010 | Merck | Active until 15.06.2030 |
mAb, monoclonal antibody; EGFR, epidermal growth factor receptor.